Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working Party

Fayers, PM; Bleehen, N. M.; Girling, D J; Stephens, R.

doi:10.1038/bjc.1991.296

Cited by 62 publications

(27 citation statements)

References 17 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EORTC QLQ-LC13 assesses lung cancer symptoms (Bergman et al, 1994). Scores were computed according to EORTC rules (Fayers et al, 1999). Questionnaires were administered before randomisation and 3 weeks after beginning of therapy in both arms; a third questionnaire was administered before the third cycle in the 3-week arm and before the second cycle in the weekly arm (Figure 1).…”

Section: Designmentioning

confidence: 99%

See 1 more Smart Citation

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study

Gridelli

Gallo²,

Maïo³

et al. 2004

Br J Cancer

147

109

View full text Add to dashboard Cite

Docetaxel (75 mg m À2 3-weekly) is standard second-line treatment in advanced non-small-cell lung cancer (NSCLC) with significant toxicity. To verify whether a weekly schedule (33.3 mg m À2 for 6 weeks) improved quality of life (QoL), a phase III study was performed with 220 advanced NSCLC patients, p75 years, ECOG PS p2. QoL was assessed by EORTC questionnaires and the Daily Diary Card (DDC). No difference was found in global QoL scores at 3 weeks. Pain, cough and hair loss significantly favoured the weekly schedule, while diarrhoea was worse. DDC analysis showed that loss of appetite and overall condition were significantly worse in the 3-week arm in the first week, while nausea and loss of appetite were more severe in the weekly arm in the third week. Response rate and survival were similar, hazard ratio of death in the weekly arm being 1.04 (95% CI 0.77 -1.39). A 3-weekly docetaxel was more toxic for leukopenia, neutropenia, febrile neutropenia and hair loss; any grade 3 -4 haematologic toxicity was significantly more frequent in the standard arm (25 vs 6%). The weekly schedule could be preferred for patients candidate to receive docetaxel as second-line treatment for advanced NSCLC, because of some QoL advantages, lower toxicity and no evidence of strikingly different effect on survival.

show abstract

Section: Designmentioning

confidence: 99%

“…The Daily Diary Card (DDC) was designed by the Medical Research Council Lung Cancer Working Party (Fayers et al, 1991;Fayers, 1995) to capture rapid and transient changes of sleeping, mood, well-being, level of activity, nausea, vomiting, appetite loss and pain. DDC was collected after 3 and 6 weeks ( Figure 1).…”

Section: Designmentioning

confidence: 99%

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study

Gridelli

Gallo²,

Maïo³

et al. 2004

Br J Cancer

147

109

View full text Add to dashboard Cite

show abstract

“…Since each course of chemotherapy is likely greatly to affect the quality of life of the patients, the mean time between each course was calculated and the profiles for each patient were realigned to this schedule. The methodology was the same as in previous MRC trials (Fayers et al, 1991;MRC Lung Cancer Working Party, 1991;.…”

Section: Methodsmentioning

confidence: 99%

“…Patients' assessment using the diary card For their first 21 weeks in the trial, the patients were asked to complete an MRC patient diary card (Fayers et al, 1991) every evening after their last meal, recording how they had been feeling during the previous 24 h. They coded their assessments as shown in Table I. The purpose of these cards was to record the patients' own daily assessments of a few key aspects of their quality of life when these were likely to be changing substantially from day to day, namely, during the period of chemotherapy and -when given -radiotherapy.…”

Section: Methodsmentioning

confidence: 99%

“…The present trial is therefore important in that clinicians reported not only on the adverse effects of treatment but also on the patients' symptoms, overall condition, and level of physical activity, and patients were asked to complete a diary card (Fayers et al, 1991) on a daily basis during chemotherapy to provide information on symptoms, level of physical activity, mood, and overall condition during the period when these were likely to be changing substantially from day to day. The diary cards thus allowed patients themselves to assess their quality of life in the above domains.…”

mentioning

confidence: 99%

See 1 more Smart Citation

A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life

Bleehen¹,

Girling²,

Machin³

et al. 1993

Br J Cancer

Self Cite

View full text Add to dashboard Cite

Summary A total of 458 eligible patients, from 21 centres, with microscopically confirmed SCLC were allocated at random to three chemotherapy regimens, each given at 3-week intervals. In two regimens, etoposide, cyclophosphamide, methotrexate and vincristine were given for a total of either three courses (ECMV3) or six courses (ECMV6). In the third regimen, etoposide and ifosfamide were given for six courses (EI6). Patients with limited disease also received radiotherapy to the primary site after the third course of chemotherapy in all three groups. As reported by clinicians, 59% of the ECMV3, 67% of the ECMV6 and 63% of the E16 patients experienced moderate or severe adverse reactions to their chemotherapy. The major symptoms of disease, cough, haemoptysis, chest pain, anorexia, and dysphagia, were palliated in 63% or more of patients and the median duration of palliation was 63% or more of survival, the results being similar in the three groups. Among patients with poor overall condition, physical activity and breathlessness on admission, the proportions who improved were higher in the EI6 group but the differences were small. In all three groups, levels of anxiety fell substantially during treatment. Levels of depression were lower and showed little change. As assessed by patients using a daily diary card, the patterns of nausea, vomiting, activity and mood, associated with courses of chemotherapy were very similar in the three groups. In the E16 group there was less dysphagia and better overall condition between courses, but these advantages need to be weighed against the inconvenience of the 24-h infusions required, compared with the 30-min infusions of the other two regimens. As reported in the companion paper (MRC Lung Cancer Working Party, 1993a) there was no statistically significant survival advantage to any of the three regimens, although the results do not exclude the possibility of a minor survival advantage with the two six-course regimens. In conclusion, there was no major clinical gain from continuing chemotherapy beyond three courses or from using the ifosfamide regimen.

show abstract

Palliative radiotherapy regimens for non-small cell lung cancer

Lester

Macbeth

Toy

et al. 2001

The Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working Party

Cited by 62 publications

References 17 publications

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study

A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life

Palliative radiotherapy regimens for non-small cell lung cancer

Contact Info

Product

Resources

About